Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People

Set Alert for People

Teva’s Ellis Is New BBA Chair

Teva UK’s director of secondary care, Andrew Ellis, who has been a member of the British Biosimilars Association’s steering group, has now been appointed as its new chair.

Appointments Biosimilars

Davis Steps Down As AAM’s Chief

The AAM is now searching for new leadership after Chip Davis announced his resignation as president and CEO of the US off-patent industry association.

Leadership United States

Lupin’s Sonig Chairs AAM Board

US industry association the AAM has revealed details of its board for 2020, which will be led by Lupin’s Alok Sonig as chair and Sandoz’ Carol Lynch as vice-chair.

Appointments Strategy

Who’s Hired? Teligent And Centrient Get New CEOs

Teligent CEO Jason Grenfell-Gardner has stepped down with immediate effect, while Centrient CEO Karl Rotthier is preparing to leave the role in March. Both firms have announced details of their replacements. Meanwhile, Stada has appointed a new chief financial officer.

Appointments Strategy

Cipla Reorganizes Its Executive Team

Ex-Torrent COO Arunesh Verma is to lead Cipla’s North America generics business, while the head of Cipla USA has been repositioned to lead the India prescription business, among other personnel changes.

Appointments Leadership

Amneal Aims To Expand Internationally

Amneal has laid out ambitious plans for 2020 to deliver value and volume growth, including by expanding internationally, augmenting organic growth through M&A and capitalizing on its pipeline of ANDAs and development projects. The firm will seek to build on its launch of 38 products in 2019 as well as benefiting from recent key appointments to its board.

Strategy United States
See All
UsernamePublicRestriction

Register